Genprex Announces New Research Identifying TROP2 as a Potential Predictive Biomarker to Reqorsa® Gene Therapy in Lung Cancer

Genprex links TROP2 biomarker to REQORSA resistance in lung cancer, but clinical validation remains pending.

What the company is saying

Genprex is highlighting new research that positions TROP2 expression as a potential predictive biomarker for response to its lead gene therapy candidate, REQORSA, in non-small cell lung cancer (NSCLC). The company frames the findings as a significant step toward precision medicine, emphasizing that low TROP2 expression correlates with primary resistance to REQORSA in both preclinical models and patient biopsies. Ryan Confer, President and CEO, is quoted to reinforce the narrative that identifying a biomarker could improve patient selection and treatment efficacy. The announcement underscores that TUSC2 protein expression is downregulated or absent in more than 80% of NSCLC cases and nearly all small cell lung cancers, supporting the rationale for REQORSA's mechanism. Genprex notes that approximately 50% of both NSCLC cell lines and patient-derived organoid models showed resistance to TUSC2 gene delivery, with low TROP2 expression consistently marking resistance. The company also points to FDA Fast Track and Orphan Drug designations for its lung cancer programs as evidence of regulatory momentum. The tone is optimistic but acknowledges that further research and clinical validation are required before TROP2 can be established as a predictive biomarker.

What the data suggests

The disclosed data show that TUSC2 tumor suppressor protein is downregulated or absent in over 80% of NSCLC cases and nearly all small cell lung cancers, providing a strong rationale for targeting this pathway. In preclinical testing, about 50% of 10 NSCLC cell lines and 50% of 12 patient-derived organoid models exhibited primary resistance to TUSC2 gene delivery, with low TROP2 expression consistently associated with resistance. Laboratory studies at MD Anderson demonstrated that TUSC2 uptake in tumor cells after REQORSA treatment was 10 to 33 times higher than in normal cells. Analysis of pretreatment tumor biopsies from clinical trial patients supported the association between TROP2 expression and treatment response. The evidence for TROP2 as a predictive biomarker is based on both preclinical and supportive clinical data, but no quantitative clinical outcomes or patient response rates are disclosed. The research is at the stage of hypothesis generation and early validation, with further studies required to confirm clinical utility. No financial, revenue, or cost data are provided, and the announcement is strictly focused on scientific findings and regulatory designations.

Analysis

The announcement is positive in tone, highlighting new research that identifies TROP2 as a potential predictive biomarker for response to REQORSA in lung cancer. The evidence presented includes both preclinical and some supportive clinical data, as well as regulatory milestones (Fast Track and Orphan Drug designations). However, many of the key claims—such as the utility of TROP2 as a biomarker and the potential for more effective, personalized treatment—are explicitly forward-looking and contingent on further research and clinical validation. The language occasionally overstates the immediate impact by suggesting a 'meaningful step' toward precision medicine, despite the need for additional studies. No financial or operational metrics are disclosed, and there is no mention of capital outlay or near-term commercial impact. The gap between narrative and evidence is moderate: while the research is promising, the benefits are long-term and not yet realised.

Risk flags

• ●The predictive value of TROP2 as a biomarker for REQORSA response is not yet clinically validated, and further research is required before it can be used to guide patient selection. This introduces significant scientific and translational risk, as preclinical correlations may not translate into clinical utility.
• ●Approximately 50% of tested NSCLC cell lines and organoid models showed primary resistance to TUSC2 gene delivery, indicating that REQORSA may not be effective in a substantial subset of patients. This could limit the commercial or clinical impact of the therapy if similar resistance rates are observed in broader patient populations.
• ●The announcement does not provide any financial data, revenue projections, or cost disclosures, making it difficult for investors to assess the company's financial health or runway. The absence of these figures increases uncertainty regarding Genprex's ability to sustain long-term clinical development.
• ●The path to regulatory approval and commercialisation remains lengthy and uncertain, as the company is still in the clinical trial phase and must demonstrate both efficacy and safety in larger patient cohorts before any market entry.

Bottom line

Genprex's announcement provides early evidence that low TROP2 expression is associated with resistance to its lead gene therapy, REQORSA, in lung cancer, suggesting TROP2 could serve as a predictive biomarker. The findings are supported by both preclinical models and analysis of patient biopsies, but no clinical efficacy or outcome data are disclosed, and the research remains at an early validation stage. The company has secured FDA Fast Track and Orphan Drug designations, which may help expedite development, but the absence of financial disclosures leaves investors without visibility into funding or runway. The timeline to any commercial or clinical impact is long, as further research and prospective clinical trials are required to confirm TROP2's utility. Investors should focus on future clinical trial results and any updates on validation of TROP2 as a biomarker. The most important takeaway is that while the scientific rationale is promising, the path to value realisation is still uncertain and long-dated.

Announcement summary

(NASDAQ:GNPX) Genprex, Inc. announced that new research identifying TROP2 expression as a potential predictive biomarker of response to its lead drug candidate, Reqorsa (quaratusugene ozeplasmid), will be presented at the 2026 EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics, taking place November 18-20, 2026 in Barcelona, Spain. The research found that low TROP2 expression was consistently associated with resistance to REQORSA across multiple preclinical models of non-small cell lung cancer (NSCLC). This association was also supported by analysis of pretreatment tumor biopsies from patients enrolled in a clinical trial evaluating REQORSA. Ryan Confer, President and Chief Executive Officer of Genprex, stated that discovering an applicable biomarker of response is a meaningful step toward a more precise approach to treating lung cancer with REQORSA. The TUSC2 tumor suppressor protein expression is downregulated or absent in more than 80% of NSCLC cases and nearly all small cell lung cancers. Previous studies have shown that REQORSA has antitumor activity, including in models resistant to targeted therapies and in immunotherapy-resistant KRAS/LKB1-mutant NSCLC. REQORSA's effects are mediated by inhibiting MAPK and mTOR signaling, inducing cell-cycle arrest and apoptosis, and activating antitumor immune responses. Approximately 50% of 10 NSCLC cell lines and 50% of 12 patient derived organoid models evaluated showed primary resistance to TUSC2 gene delivery. Protein-expression analyses consistently identified low TROP2 expression as a marker associated with resistance across multiple preclinical models. Analysis of pretreatment tumor biopsies from patients enrolled in a TUSC2 gene therapy clinical trial supported the association between TROP2 expression and treatment response. Experimental manipulation of TROP2 expression altered TUSC2-induced cancer cell death, suggesting that TROP2-dependent signaling may play a role in therapeutic response. Further research is underway to understand these context-dependent effects. The findings identify TROP2 as a potential predictive biomarker for response to REQORSA and suggest that modulating TROP2 signaling may be a novel strategy to enhance the therapeutic efficacy of REQORSA in NSCLC. Additional research and prospective clinical evaluation will be required to establish TROP2's predictive utility in patients receiving REQORSA. The Genprex-supported poster, titled 'TROP2 Predicts Response to TUSC2 Gene Therapy (Quaratusugene Ozeplasmid) and Its Modulation Sensitizes Non-Small Cell Lung Cancer to Treatment,' will be presented on November 18, 2026, from 12:00–6:00 p.m. CET at the CCIB in Barcelona, Spain (Abstract Number: 108, Poster Board Number: PB-108). The poster is expected to be available on Genprex's website following the presentation, subject to applicable conference disclosure requirements. REQORSA consists of a plasmid containing the TUSC2 gene encapsulated in non-viral lipid-based nanoparticles in a lipoplex form (the Oncoprex Delivery System), which has a positive charge. REQORSA is injected intravenously and specifically targets cancer cells, delivering the functioning TUSC2 gene to negatively charged cancer cells while minimizing uptake by normal tissue. Laboratory studies at MD Anderson show that the uptake of TUSC2 in tumor cells in vitro after REQORSA treatment was 10 to 33 times the uptake in normal cells. Genprex's lead oncology program, REQORSA, is being developed for the treatment of lung cancer and is being evaluated in the Acclaim-1 and Acclaim-3 clinical trials for non-small cell lung cancer and small cell lung cancer, respectively. The U.S. Food and Drug Administration (FDA) has granted Fast Track Designation to both lung cancer programs and Orphan Drug designation to the small cell lung cancer program. Genprex is also advancing an earlier stage gene therapy program for diabetes, designed to restore insulin-producing capability through the expression of key pancreatic transcription factors.

Disagree with this article?